Breaking News, Collaborations & Alliances

Biogen Exercises Option Under ATV Alliance with Denali to Advance Alzheimer’s Antibodies

Program uses Denali’s Antibody Transport Vehicle technology to cross the blood-brain barrier and aims to increase target engagement.

Biogen and Denali Therapeutics Inc. announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV: Aβ). Accumulation of Aβ plaque in the brain is a defining feature of Alzheimer’s disease (AD). Using Denali’s ATV platform to cross the blood-brain barrier (BBB), ATV:Aβ is designed to increase brain exposure and target engagement of antibody therapeutics directed against Aβ, which may enable improved plaque clearance and/or reduced a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters